1. What Is the Lymphoma Drug Market?
The Lymphoma Drug Market covers the systemic therapies used to treat the non-Hodgkin lymphoma subtypes including diffuse large B cell lymphoma, follicular lymphoma, mantle cell lymphoma, and marginal zone lymphoma, and Hodgkin lymphoma. The market spans the RCHOP chemotherapy backbone plus rituximab anti-CD20 for the B cell NHL, the bispecific T cell engagers glofitamab and epcoritamab, and the CD19 and CD20 CAR-T cell therapies. The checkpoint inhibitors nivolumab and pembrolizumab treat the Hodgkin lymphoma that the CD30 antibody-drug conjugate brentuximab vedotin also addresses. Lymphoma drug development has produced the ADC brentuximab vedotin approval for the CD30-expressing Hodgkin lymphoma and the PTCL. The polatuzumab vedotin CD79b ADC treats the relapsed DLBCL in combination with bendamustine and rituximab. The loncastuximab tesirine treats the relapsed DLBCL through the antibody-drug conjugate approach that has extended across multiple CD79b, CD19, and CD30 lymphoma targets. The lymphoma drug market is being transformed by the mosunetuzumab bispecific antibody approval for the multiply relapsed follicular lymphoma achieving 59 percent objective response rate. The glofitamab approval for the relapsed DLBCL after two prior therapies achieves 35 percent complete response. These demonstrate the bispecific T cell engager as the off-the-shelf cellular immunotherapy alternative to the autologous CAR-T that requires the 4 to 6-week patient-specific manufacturing.
2. Lymphoma Drug Market Size & Forecast
3. Emerging Technologies
- CAR-T cell therapy axicabtagene ciloleucel ZUMA-7 and lisocabtagene maraleucel TRANSFORM trials demonstrated superior event-free survival versus standard second-line chemotherapy plus autologous SCT for the early relapsed or primary refractory DLBCL. The DLBCL previously required the salvage chemotherapy bridge to the autologous transplant. The CAR-T is now the second-line standard replacing autologous transplant for the early DLBCL relapse.
- Glofitamab bispecific CD20 by CD3 fixed-duration 12-cycle treatment achieved 35 percent complete response rate in the multiply relapsed or refractory DLBCL with the 12-month DOR of the complete response patients. This provides the off-the-shelf bispecific alternative to the personalised CAR-T manufacturing. The patient who requires the urgent treatment that the 4 to 6-week CAR-T manufacturing cannot provide benefits from the off-the-shelf bispecific.
- Mosunetuzumab bispecific CD20 by CD3 antibody for the relapsed or refractory follicular lymphoma achieved 59 percent ORR and 36 percent complete response rate in the CELESTIMO trial from the fixed-duration 8-cycle treatment. The bispecific T cell engager is now the effective and off-the-shelf option for the indolent B cell lymphoma. The time-limited treatment and the preserved retreatment option that the reversible B cell depletion allows are the advantages over the CAR-T.
- Loncastuximab tesirine Zynlonta CD19-targeting ADC with the SG3199 PBD pyrrolobenzodiazepine payload for the relapsed DLBCL achieved 48 percent ORR and 24 percent CR in the LOTIS-2 trial. This represents the third approved ADC mechanism for the B cell lymphoma. The CD79b polatuzumab vedotin and the CD30 brentuximab vedotin are the other two approved ADC mechanisms for lymphoma.
Such innovations are driving change across adjacent industries too. Discover more in our Immunotherapy Market.
4. Key Market Opportunity
A significant commercial opportunity in the Lymphoma Drug market comes from bispecific antibody expansion, where off-the-shelf CD20 by CD3 bispecific antibodies accessible without the manufacturing timeline of autologous CAR-T are expanding treatment access in relapsed B-cell lymphoma. Companies with approved bispecific lymphoma antibodies capture the access-advantage opportunity. Another growth driver centers on CAR-T earlier-line use in DLBCL. As bispecific antibody adoption grows and CAR-T moves into earlier DLBCL treatment, the addressable opportunity is expanding across lymphoma treatment lines with both autologous cell therapy and off-the-shelf bispecific approaches.
5. Top Companies in the Lymphoma Drug Market
The following organisations hold leading positions in the Lymphoma Drug Market. The full report provides revenue share, SWOT analysis, and competitive benchmarking for each player.
- Roche
- AbbVie
- AstraZeneca
- BeiGene
- Bristol-Myers Squibb
- Eli Lilly
- Genmab
- Gilead Sciences
- Johnson and Johnson
- Novartis
- Pfizer
- Takeda
- Incyte
- ADC Therapeutics
6. Market Segmentation
The Lymphoma Drug Market is analysed across 4 segmentation dimensions. Revenue data, growth rates, and competitive intensity by sub-segment are available in the full report.
| Segmentation | Sub-Segments |
|---|---|
| By Lymphoma Type | DLBCL FL CLL-SLL MCL HL PTCL |
| By Drug Class | Anti-CD20 BTK Inhibitor CAR-T Bispecific Antibody Checkpoint Inhibitor |
| By Line | First-Line Second-Line Relapsed |
| By Geography | North America The U.S. Canada Europe The UK Germany France Italy Spain Denmark Netherlands Finland Sweden Norway Russia Austria Poland Rest of Europe Asia Pacific China Japan India South Korea Australia Indonesia Vietnam Philippines Singapore Taiwan Thailand Rest of Asia Pacific Latin America Brazil Mexico Argentina Rest of South America Middle East and Africa GCC Countries Israel South Africa Rest of Middle East and Africa |
7. Key Market Trends (2026–2034)
Three major forces are shaping the Lymphoma Drug Market trajectory over the forecast period:
CAR-T ZUMA-7 and TRANSFORM Trials Demonstrating Superior EFS Over Standard Second-Line Chemotherapy Plus AutoSCT for Early Relapsed and Primary Refractory DLBCL Have Established CAR-T as the Second-Line Standard Replacing Autologous Transplant for High-Risk Early DLBCL.AbbVie and Genmab's epcoritamab demonstrated 39% complete response rate in relapsed refractory DLBCL as a subcutaneous weekly injection, and Roche's glofitamab demonstrated 39% complete response with a fixed 12-cycle regimen with 61% of complete responses remaining at 12 months. The step-up dosing protocols for both agents were designed to manage cytokine release syndrome in outpatient settings where hospitalisation would otherwise be required for conventional CAR-T, creating a practical advantage for community oncology centres without cellular therapy infrastructure. Combination trials with lenalidomide, polatuzumab, and obinutuzumab are advancing to enhance bispecific response depth in patients achieving partial rather than complete response.
Glofitamab Bispecific 35 Percent Complete Response in Multiply Relapsed DLBCL With Fixed 12-Cycle Treatment Provides the Urgent Off-the-Shelf Bispecific Alternative to the 4 to 6-Week CAR-T Manufacturing That Cannot Serve the Patient Requiring Immediate Treatment.Roche's polatuzumab vedotin demonstrated improved progression-free and overall survival when combined with rituximab-bendamustine versus rituximab-bendamustine alone in relapsed DLBCL, and its subsequent combination with R-CHOP in first-line disease in POLARIX extended benefit into newly diagnosed patients. Polatuzumab delivers MMAE anti-tubulins to CD79b-expressing B cells through a cleavable linker system that generates bystander killing of antigen-negative tumour cells within the lymphoma microenvironment. The POLARIX benefit was modest in overall survival but statistically significant for progression-free survival in a population defined by high IPI score, supporting first-line incorporation for poor-prognosis DLBCL that requires intensification beyond standard R-CHOP.
Mosunetuzumab Fixed-Duration 8-Cycle Bispecific 59 Percent ORR in Relapsed Follicular Lymphoma With Preserved Retreatment Option From Reversible B Cell Depletion Represents the Time-Limited Off-the-Shelf Alternative to CAR-T for the Indolent Lymphoma Setting.ADC Therapeutics's loncastuximab tesirine targeting CD19 demonstrated 48% overall response rate in LOTIS-2 in heavily pre-treated DLBCL, providing an additional ADC option alongside polatuzumab for patients who relapse after both second-line therapy and CAR-T. The PBD dimer payload of loncastuximab creates DNA cross-links that are particularly potent in proliferating lymphoma cells and does not require CD19 antigen density above a threshold for cytotoxic activity. The convergence of ADC, bispecific antibody, and CAR-T options across relapsed B-cell lymphoma is creating a sequencing challenge for oncologists who must integrate products with overlapping targets and mechanisms across multiple treatment lines.
For related market intelligence, see the Oncology Drug Market.
8. Segmental Analysis
By drug class, the anti-CD20 monoclonal antibody segment dominated the Lymphoma Drug Market in 2025, as Roche's Rituxan and Gazyva anchored treatment across B-cell lymphomas in combination with chemotherapy, generating the broadest prescriber base in the disease.
By line of therapy, the relapsed and refractory segment is projected to register the highest growth rate through 2034, as Roche's Lunsumio and Columvi and AbbVie and Genmab's Epkinly establish off-the-shelf bispecific T-cell engagers as a scalable alternative to cell therapy in later-line disease.
9. Regional Analysis
Regional demand patterns across the Lymphoma Drug Market reflect differences in regulation, technological maturity, and capital investment.
Largest Market Share
North America dominated the Lymphoma Drug Market in 2025, accounting for approximately 43% of global revenue, due to US premium pricing for CAR-T therapies, bispecific antibodies, and obinutuzumab and the concentration of Roche, Genmab, Gilead, and Bristol-Myers Squibb commercial operations. Moreover, bispecific antibody and CAR-T adoption are most advanced in US haematology. In addition, rituximab combination chemotherapy sustains treatment volume. Regional dominance is attributed to this combination of pricing environment and innovative therapy adoption.
Highest CAGR Region
Europe is projected to register the highest CAGR in the Lymphoma Drug Market through 2034, driven by expanding bispecific antibody and CAR-T access across European healthcare systems and the large lymphoma patient population in Europe. The region is also witnessing obinutuzumab adoption growing in follicular lymphoma. Moreover, clinical trial infrastructure for novel lymphoma regimens sustains innovation. The combination of these demand drivers and access expansion positions Europe for sustained growth outperformance through 2034.
10. Full Report with Exclusive Insights
The complete published market report includes an in-depth analysis of market dynamics, industry trends, competitive landscape, regional outlook, and future growth opportunities. The study provides detailed market sizing and forecasts across key segments and geographies, along with comprehensive insights into drivers, restraints, opportunities, challenges, technological advancements, regulatory landscape, and evolving consumer and industry trends. The report also features company profiles, strategic developments, market share analysis, and actionable recommendations to support informed business decision-making. Additionally, the syndicated report package typically includes forecast datasets, charts and figures, research methodology, and analyst support for strategic interpretation and planning.
Advanced Strategic & Custom Intelligence
In addition to the standard syndicated report package, TrendX Insights can provide the following advanced strategic analyses and customized intelligence solutions for any market:
Standard Report Coverage
- • Competitor Analysis
- • Country Trade Analysis
- • Import & Export Analysis
- • Porter’s Five Forces Analysis
- • SWOT Analysis by Companies
- • TrendX Insights Quadrant Positioning
- • Pricing Analysis
- • Detailed Macro-Economic Indicators Assessment
- • List of Raw Material Suppliers
- • Regulatory Framework Assessment
- • Supply Chain Resilience Mapping
- • Value Chain Analysis
- • Technology Adoption Trends and Innovation Tracking
- • Custom Company Profiling and Benchmarking
Exclusive Sections With Additional Cost
- • Agentic AI Readiness Score
- • TAM, SAM, and SOM Analysis
- • AI Act & Privacy Compliance Audit
- • Channel Partner Ecosystem Mapping
- • China + 1 Strategy Analysis
- • Circular Economy Opportunities Assessment
- • Competitor Benchmarking KPI Analysis
- • Country-Level Opportunity Mapping
- • Digital Maturity Matrix
- • Ecosystem Interdependency Mapping
- • ESG & Decarbonization Roadmap
- • Geopolitical Friction Scorecard
- • Geopolitical Risk Assessment
- • Humanoid Workforce Impact Analysis
- • Investment Heatmap
- • List of Distributors and Channel Partners
- • Market Entry Strategy Assessment
- • Mergers & Acquisitions (M&A) Analysis
- • Patent & Intellectual Property (IP) Analysis
- • Pilot Project Analysis
- • Potential High-Growth Region/Country Investment Assessment
- • Product Comparison Analysis
- • Product Revenue Analysis
- • R&D Investment Analysis in Emerging Technologies
- • Raw Material Scarcity Forecast
Note: For highly customized requirements, deeper strategic assessments, company-specific intelligence, or tailored consulting support, please contact TrendX Insights.
Full Report with Exclusive Insights
Available to clients on request
Explore Our Published Reports Library
This page covers market-level data estimates. For comprehensive published research reports including full methodology, primary data, and detailed company profiles, browse the TrendX Insights Published Reports Library.
Visit Published Reports Library ›11. Related Market Reports
Frequently Asked Questions
The Lymphoma Drug Market was valued at USD 15.48 Bn in 2025 and is projected to reach USD 32.27 Bn by 2034, growing at a CAGR of 8.5% over the 2026–2034 forecast period.
The Lymphoma Drug Market is projected to grow at a CAGR of 8.5% from 2026 to 2034.
North America dominated the Lymphoma Drug Market in 2025, accounting for approximately 43% of global revenue, due to US premium pricing for CAR-T therapies, bispecific antibodies, and obinutuzumab and the concentration of Roche, Genmab, Gilead, and Bristol-Myers Squibb commercial operations.
The leading companies in the Lymphoma Drug Market include Roche, AbbVie, AstraZeneca, BeiGene, Bristol-Myers Squibb, Eli Lilly, Genmab, Gilead Sciences, Johnson and Johnson, Novartis, Pfizer, Takeda, Incyte, ADC Therapeutics.
Car-t zuma-7 and transform trials demonstrating superior efs over standard second-line chemotherapy plus autosct for early relapsed and primary refractory dlbcl have established car-t as the second-line standard replacing autologous transplant for high-risk early dlbcl.
By drug class, the anti-CD20 monoclonal antibody segment dominated the Lymphoma Drug Market in 2025, as Roche's Rituxan and Gazyva anchored treatment across B-cell lymphomas in combination with chemotherapy, generating the broadest prescriber base in the disease.
How to Order
Purchasing a TrendX Insights report is straightforward. Our process is designed to be transparent and risk-free for buyers, with a 20% upfront model and full delivery before the balance payment.
This is the price of the syndicated report. Any custom inclusions beyond the Table of Contents will be scoped and priced separately. For the full list of what is covered in the syndicated report, refer to the Table of Contents tab.
A curated, condensed version of this report for students, researchers, and academic institutions. Ideal for thesis work, dissertations, and academic projects. Delivered as PDF to your institutional email.
Valid student ID or institutional email required. For educational and non-commercial use only.